3,4-Diisopropyl-1-methyl-pyrrole-2,5-dione | 128040-94-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3,4-Diisopropyl-1-methyl-pyrrole-2,5-dione
• 英文别名: 1-Methyl-3,4-di(propan-2-yl)pyrrole-2,5-dione
• CAS: 128040-94-8
• 化学式: C₁₁H₁₇NO₂
• 分子量: 195.261
• InChiKey: WQQPGELDKZXIHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-甲基马来酰亚胺 在 三乙烯二胺 、 potassium iodide 作用下， 生成 3,4-Diisopropyl-1-methyl-pyrrole-2,5-dione
  参考文献：
  名称：

  Effects of iodide ion and amines on the free radical alkylation of 1,4-enediones by alkylmercury halides

  摘要：

  DOI：

  10.1016/s0040-4039(00)97040-0

文献信息

• Compounds and methods of treating retinal degeneration
  申请人：CASE WESTERN RESERVE UNIVERSITY

  公开号：US11191752B2

  公开（公告）日：2021-12-07

  This application relates to compounds and methods of treating retinal degeneration associated with inherited rhodopsin mutations in the ocular tissue of a subject. The retinal degeneration, can include, for example, macular degeneration, a including age-related macular degeneration, Stargardt disease, and retinitis pigmentosa. The retinitis pigmentosa can include autosomal dominate retinitis pigmentosa associated with a P23H RHO mutation. A method of treating retinal degeneration in a subject includes administering to the subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) acts as a chaperone of rhodopsin.

  本申请涉及治疗与受试者眼组织中遗传性视网膜视蛋白突变有关的视网膜变性的化合物和方法。视网膜变性可包括例如黄斑变性，包括老年性黄斑变性、Stargardt 病和视网膜色素变性。视网膜色素变性可包括与 P23H RHO 突变相关的常染色体显性视网膜色素变性。一种治疗受试者视网膜变性的方法包括向受试者施用治疗有效量的式(I)化合物，其中式(I)化合物作为视紫红质的伴侣蛋白。
• RUSSELL, GLEN A.;BYEONG, HYO KIM, SYNLETT,(1990) N, C. 87-88
  作者：RUSSELL, GLEN A.、BYEONG, HYO KIM

  DOI：——

  日期：——
• COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION
  申请人：CASE WESTERN RESERVE UNIVERSITY

  公开号：US20200230119A1

  公开（公告）日：2020-07-23

  This application relates to compounds and methods of treating retinal degeneration associated with inherited rhodopsin mutations in the ocular tissue of a subject. The retinal degeneration, can include, for example, macular degeneration, a including age-related macular degeneration, Stargardt disease, and retinitis pigmentosa. The retinitis pigmentosa can include autosomal dominate retinitis pigmentosa associated with a P23H RHO mutation. A method of treating retinal degeneration in a subject includes administering to the subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) acts as a chaperone of rhodopsin.
• Disulfide Bridging Conjugates
  申请人：Sorrento Therapeutics, Inc.

  公开号：US20210052738A1

  公开（公告）日：2021-02-25

  Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.
• Effects of iodide ion and amines on the free radical alkylation of 1,4-enediones by alkylmercury halides
  作者：Glen A Russell、Hyo Kim Byeong

  DOI：10.1016/s0040-4039(00)97040-0

  日期：1990.1